Angiotensin-converting-enzyme inhibition counteracts angiotensin II-mediated endothelial cell dysfunction by modulating the p38/SirT1 axis

Journal of Hypertension

Volumn 31, Issue 10, 2013, Pages 1972-1983

  Marampon, Francesco ^a,b   Gravina, Giovanni L ^a   Scarsella, Luca ^a   Festuccia, Claudio ^a   Lovat, Francesca ^c   Ciccarelli, Carmela ^a   Zani, Bianca M ^a   Polidoro, Lorella ^b   Grassi, Davide ^b   Desideri, Giovambattista ^b   Evangelista, Stefano ^d   Ferri, Claudio ^b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c OHIO STATE UNIVERSITY   (United States)

^d Menarini Ricerche SpA   (Italy)

Author keywords

ACE inhibitor; Endothelial dysfunction; SirT1; Zofenopril

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; CASPASE 3; CASPASE 8; DIPEPTIDYL CARBOXYPEPTIDASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; SIRTINOL; SIRTUIN 1; SUPEROXIDE; SYNAPTOPHYSIN; ZOFENOPRILAT;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CYTOPLASM; CYTOTOXICITY; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NICK END LABELING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; WESTERN BLOTTING;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; APOPTOSIS; CAPTOPRIL; CELL NUCLEUS; CELL SURVIVAL; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; MAP KINASE KINASE 6; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; REACTIVE OXYGEN SPECIES; SIRTUIN 1; SUPEROXIDES;

EID: 84884412294     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283638b32     Document Type: Article

References (65)

1. Johnson FB, Sinclair DA, Guarente L. Molecular biology of aging. Cell 1999; 96:291-302.
2. Lee R, Channon KM, Antoniades C. Therapeutic strategies targeting endothelial function in humans: clinical implications. Curr Vasc Pharmacol 2012; 10:77-93.
3. Fuchs-Tarlovsky V. (2012) Role of antioxidants in cancer therapy. Nutrition 2013; 29:15-21.
4. Maiese K, Chong ZZ, Hou J, Shang YC. Oxidative stress: biomarkers and novel therapeutic pathways. Exp Gerontol 2010; 45:217-234.
5. Wang JC, Bennett M. Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res 2012; 111:245-259.
6. Chen AF, Chen DD, Daiber A, Faraci FM, Li H, Rembold CM, Laher I. Free radical biology of the cardiovascular system. Clin Sci [Lond] 2012; 123:73-91.
7. Grassi D, Desideri G, Ferri C. Cardiovascular risk and endothelial dysfunction: the preferential route for atherosclerosis. Curr Pharm Biotechnol 2011; 12:1343-1353.
8. Chong ZZ, Shang YC, Maiese K. Cardiovascular disease and mTOR signaling. Trends Cardiovasc Med 2011; 21:151-155.
9. Han J, Shuvaev VV, Muzykantov VR. Targeted interception of signaling reactive oxygen species in the vascular endothelium. Ther Deliv 2012; 3:263-276.
10. Halliwell B. Free radicals and antioxidants: updating a personal view. Nutr Rev 2012; 70:257-265.
11. Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22:1257-1266.
12. Donnini S, Terzuoli E, Ziche M, Morbidelli L. Sulfhydryl angiotensinconverting enzyme inhibitor promotes endothelial cell survival through nitric-oxide synthase, fibroblast growth factor-2, and telomerase cross-talk. J Pharmacol Exp Ther 2010; 332:776-784.
13. Verdecchia P, Gentile G, Angeli F, Reboldi G. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. Ther Adv Cardiovasc Dis 2012; 6:81-91.
14. Nakashima H, Suzuki H, Ohtsu H, Chao JY, Utsunomiya H, Frank GD, Eguchi S. Angiotensin II regulates vascular and endothelial dysfunction: Recent topics of angiotensin ii type-1 receptor signaling in the vasculature. Curr Vasc Pharmacol 2006; 4:67-78.
15. Desideri G, Bravi MC, Tucci M, Croce G, Marinucci MC, Santucci A, et al. Angiotensin II inhibits endothelial cell motility through an AT1-dependent oxidant-sensitive decrement of nitric oxide availability. Arterioscler Thromb Vasc Biol 2003; 23:1218-1223.
16. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292:C82-C97.
17. Manrique C, Lastra G, Gardner M, Sowers JR. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am 2009; 93:569-582.
18. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988; 77 (6 pt 2):13-14.
19. Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22:1257-1266.
20. Desideri G, Grassi D, Croce G, Bocale R, Tiberti S, Evangelista S, et al. Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Mediators Inflamm 2008; 2008:305087.
21. Arakawa K, Urata H. Hypothesis regarding the pathophysiological role of alternative pathways of angiotensin II formation in atherosclerosis. Hypertension 2000; 36:638-641.
22. Kinoshita A, Urata H, Bumpus FM, Husain A. Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from the human heart. J Biol Chem 1991; 266:19192-19197.
23. Snyder RA, Kaempfer CE, Wintroub BU. Chemistry of a human monocyte-derived cell line (U937): identification of the angiotensin I-converting activity as leukocyte cathepsin G. Blood 1985; 65:176-182.
24. Bar-Sagi D, Hall A. Ras, and Rho GTPases: a family reunion. Cell 2000; 103:227-238.
25. Lander HM, Milbank AJ, Tauras JM, Hajjar DP, Hempstead BL, Schwartz GD, et al. Redox regulation of cell signalling. Nature 1996; 381:380-381.
26. Maekawa Y, Ohishi M, Ikushima M, Yamamoto K, Yasuda O, Oguro R, et al. Klotho protein diminishes endothelial apoptosis and senescence via a mitogen-activated kinase pathway. Geriatr Gerontol Int 2011; 11:510-516.
27. Joshi MB, Philippova M, Ivanov D, Allenspach R, Erne P, Resink TJ. Tcadherin protects endothelial cells from oxidative stress-induced apoptosis. FASEB J 2005; 19:1737-1739.
28. Polidoro L, Properzi G, Marampon F, Gravina GL, Festuccia C, Di Cesare E, et al. Vitamin D protects human endothelial cells from H(2)O (2) oxidant injury through the Mek/Erk-Sirt1 axis activation. J Cardiovasc Transl Res 2012.
29. Midwinter RG, Vissers MC, Winterbourn CC. Hypochlorous acid stimulation of the mitogen-activated protein kinase pathway enhances cell survival. Arch Biochem Biophys 2001; 394:13-20.
30. van Gorp RM, Heeneman S, Broers JL, Bronnenberg NM, van Dam-Mieras MC, Heemskerk JW. Glutathione oxidation in calcium-and p38 MAPK-dependent membrane blebbing of endothelial cells. Biochim Biophys Acta 1999; 19:129-138.
31. Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999; 13:1231-1238.
32. Chae YJ, Kim CH, Ha TS, Hescheler J, Ahn HY. Sachinidis A.Epigallocatechin-3-O-gallate inhibits the angiotensin II-induced adhesion molecule expression in human umbilical vein endothelial cell via inhibition of MAPK pathways. Cell Physiol Biochem 2007; 20:859-866.
33. Meloche S, Landry J, Huot J, Houle F, Marceau F, Giasson E. p38 MAP kinase pathway regulates angiotensin II-induced contraction of rat vascular smooth muscle. Am J Physiol Heart Circ Physiol 2000; 279:H741-H751.
34. Runchel C, Matsuzawa A, Ichijo H. Mitogen-activated protein kinases in mammalian oxidative stress responses. Antioxid Redox Signal 2011; 15:205-218.
35. Passariello CL, Zini M, Nassi PA, Pignatti C, Stefanelli C. Upregulation of SIRT1 deacetylase in phenylephrine-treated cardiomyoblasts. Biochem Biophys Res Commun 2011; 407:512-516.
36. Satoh A, Stein L, Imai S. The role of mammalian sirtuins in the regulation of metabolism, aging, and longevity. Handb Exp Pharmacol 2011; 206:125-162.
37. Potente M, Dimmeler S. Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle 2008; 7:2117-2122.
38. Kao CL, Chen LK, Chang YL, Yung MC, Hsu CC, Chen YC, et al. Resveratrol protects human endothelium from H[2]O[2]-induced oxidative stress and senescence via SirT1 activation. J Atheroscler Thromb 2010; 17:970-979.
39. Ota H, Akishita M, Eto M, Iijima K, Kaneki M, Ouchi Y. SirT1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol 2007; 43:571-579.
40. Wang F, Chen HZ, Lv X, Liu DP. SIRT1 as a novel potential treatment target for vascular aging and age-related vascular diseases. Curr Mol Med 2013; 13: 155-64..
41. Garlanda C, Dejana E. Heterogeneity of endothelial cells. Specific markers. Arterioscler Thromb Vasc Biol 1997; 17:1193-1202.
42. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensinconverting enzyme inhibitor zofenopril. J Int Med Res 2005; 33:42-54.
43. Ferrario CM, Chappell MC, Dean RH, Iyer SN. Novel angiotensin peptides regulate blood pressure, endothelial function, and natriuresis. J Am Soc Nephrol 1998; 9:1716-1722.
44. Fu M, Liu M, Sauve AA, Jiao X, Zhang X, Wu X, Powell MJ, et al. Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol 2006; 26:8122-8135.
45. Marampon F, Ciccarelli C, Zani BM. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Mol Cancer 2006; 5:31.
46. Ciccarelli C, Marampon F, Scoglio A, Mauro A, Giacinti C, De Cesaris P, Zani BM. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells. Mol Cancer 2005; 4:41.
47. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modification to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986; 89: 271-277.
48. Marampon F, Gravina GL, Di Rocco A, Bonfili P, Di Staso M, Fardella C, Polidoro L, et al. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. Mol Cancer Ther 2011; 10:159-168.
49. Lowry OH, Rosenburgh NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-275.
50. Marampon F, Casimiro MC, Fu M, Powell MJ, Popov VM, Lindsay J, et al. Nerve growth factor regulation of cyclin D1 in PC12 cells through a p21RAS extracellular signal-regulated kinase pathway requires cooperative interactions between Sp1 and nuclear factor-kappaB. Mol Biol Cell 2008; 19:2566-2578.
51. Chaudhary PM, Eby MT, Jasmin A, Kumar A, Liu L, Hood L. Activation of the NF-kappaB pathway by caspase 8 and its homologs. Oncogene 2000; 39:4451-4460.
52. Khan BV, Sola S, Lauten WB, Natarajan R, Hooper WC, Menon RG, et al. Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care 2004; 27:1712-1715.
53. Chopra M, McMurray J, Stewart J, Dargie HJ, Smith WE. Free radical scavenging: a potentially beneficial action of thiol-containing angiotensin converting enzyme inhibitors. Biochem Soc Trans 1990; 18:1184-1185.
54. Napoli C, Sica V, de Nigris F, Pignalosa O, Condorelli M, Ignarro LJ, Liguori A. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148:e5.
55. Buikema H, Monnink SH, Tio RA, Crijns HJ, de Zeeuw D, van Gilst WH. Br J Comparison of zofenopril and lisinopril to study the role of sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Pharmacol 2000; 130:1999-2007.
56. de Nigris F, D'Armiento FP, Somma P, Casini A, Andreini I, Sarlo F, et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol 2001; 81:107-115.
57. Napoli C, Bruzzese G, Ignarro LJ, Crimi E, de Nigris F, Williams-Ignarro S, et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008; 156:1154.
58. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Pellegrini M, Boccioletti V, et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20:443-450.
59. Verdecchia P, Gentile G, Angeli F, Reboldi G. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. Ther Adv Cardiovasc Dis 2012; 6:81-91.
60. Munzel T, Keaney JF Jr. Are ACE inhibitors a 'magic bullet' against oxidative stress? Circulation 2001; 104:1571-1574.
61. Rahman S, Islam R. Mammalian SIRT1: insights on its biological functions. Cell Commun Signal 2011; 9:11.
62. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303:2011-2015.
63. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116:551-556.
64. Jin Q, Yan T, Ge X, Sun C, Shi X, Zhai Q. Cytoplasm-localized SIRT1 enhances apoptosis. J Cell Physiol 2007; 213:88-97.
65. Hong EH, Lee SJ, Kim JS, Lee KH, Um HD, Kim JH, et al. Ionizing radiation induces cellular senescence of articular chondrocytes via negative regulation of SIRT1 by p38 kinase. J Biol Chem 2010; 285:1283-1295.